News
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive ...
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...
Albertsons CEO Susan Morris said she had to "double-check the numbers" when she saw how much cottage cheese the chain was selling.
By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, ...
In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...
More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...
Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...
Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...
18h
Money Talks News on MSNYour Wegovy Access Just Changed: What Patients Need to Know NowNovo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what millions of weight-loss drug users need to know before their next ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results